Freedom Together Foundation Has $1.07 Million Holdings in Pfizer Inc. (NYSE:PFE)

Freedom Together Foundation decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 80.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,293 shares of the biopharmaceutical company's stock after selling 161,000 shares during the quarter. Pfizer makes up approximately 0.1% of Freedom Together Foundation's portfolio, making the stock its 17th biggest position. Freedom Together Foundation's holdings in Pfizer were worth $1,069,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. PSI Advisors LLC lifted its holdings in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton raised its stake in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the period. Finally, Beam Wealth Advisors Inc. raised its stake in shares of Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after purchasing an additional 401 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on PFE shares. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of PFE stock traded up $0.81 during trading on Monday, hitting $23.09. The company had a trading volume of 77,367,014 shares, compared to its average volume of 40,672,219. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $131.25 billion, a P/E ratio of 16.37, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The stock's 50-day moving average price is $24.02 and its 200 day moving average price is $25.52. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business earned $0.82 earnings per share. The company's revenue was down 7.8% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.45%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.